Humana's Recent Challenges and TD Cowen's Outlook
Recently, TD Cowen has reaffirmed its Buy rating on Humana (NYSE: HUM) while keeping a steady price target at $402.00. The firm is addressing the recent reveal from Humana that only 25% of its members will hold plans rated 4 Stars and above in the upcoming year, a drastic decline from 94% recorded in 2024. This significant change is particularly noticeable in contract H5216, where approximately 45% of its members will see their ratings drop from 4.5 to 3.5 stars.
Impact of Star Ratings on Premiums
The change in star ratings is anticipated to have a considerable effect on Humana's premiums in 2026. The company contends that the decrease is due to narrowly missing higher industry benchmarks on various measures, and they are in the process of contesting some of these results. Star ratings play a critical role as plans rated 4.0 stars or higher receive a 5% quality bonus adjustment to benchmark rates, while those rated 4.5 stars or above enjoy a more favorable 70% rebate compared to a 65% rebate for ratings between 3.5 and 4.0 stars.
Financial Predictions and Future Considerations
The potential financial impact from these changes on Humana's earnings per share (EPS) and profit margins is contingent upon multiple factors. This includes how well Humana can counteract premium losses by adjusting benefits, the total Medicare Advantage rate for 2026, the version 28 (v28) impact, and the rising cost trends for the upcoming year. Additionally, the enrollment dynamics will also play a role in how these changes affect Humana's financial landscape.
Leeway with CMSS
Plans that are experiencing lower star ratings might find more flexibility with the Centers for Medicare & Medicaid Services (CMS) total beneficiary cost reduction limits. It could enable them to maintain margins if they opt to exercise this choice, which could be a strategic move for Humana moving forward.
Market Reactions and Analyst Ratings
Humana is currently encountering obstacles due to its considerable decline in Medicare Advantage Star Ratings for the upcoming year. The company’s contract H5216, which encompasses a large segment of its Medicare Advantage membership, experienced a ratings drop from 4.5 stars to 3.5 stars. As a result, the proportion of members enrolled in 4-star and above plans fell sharply in 2025. Despite these setbacks, Barclays still holds an Overweight rating and a price target of $364.00 on Humana.
Competitors’ Perspectives
In contrast, Morgan Stanley and JPMorgan have upheld their Equal-weight and Neutral ratings toward Humana. However, the position taken by Leerink Partners has shifted, downgrading Humana's stock from Outperform to Market Perform due to apprehensions regarding the company's performance outlook linked to decreasing star ratings.
Evolent Health's Connection
Additionally, it's important to note the potential implications for Evolent Health (NYSE: EVH), a key player that contributes significantly—about 21.8%—to Evolent's revenue. The updates from Humana are likely to resonate within Evolent’s operations, but JPMorgan remains optimistic with its Overweight rating and a $45.00 price target for Evolent Health, highlighting that the fees for managing specialty care within Medicare Advantage contracts remain unaffected.
Insights from InvestingPro
In response to Humana's recent challenges, data from InvestingPro provides further insights for investors. Although there could be implications on future premiums due to the star rating changes, Humana has exhibited strong financial metrics. As of Q2 2024, the company's revenue reached an impressive $112.04 billion, alongside a healthy revenue growth rate of 13.48% for the same period.
Commitment to Shareholder Returns
InvestingPro Tips reveal that Humana has sustained dividend payments for 14 consecutive years, with a commendable increase in dividends for the past 7 years. This commitment to rewarding shareholders could offer reassurance to those troubled by the potential financial effects of the star rating adjustments.
Stock Performance and Investor Considerations
Humana's stock performance has been responsive to the recent news regarding the star rating decline, noted by a 20.95% decrease over the past month. Nonetheless, with its P/E ratio standing at 17.41 and a price-to-book ratio of 2.02, the company may present attractive valuation opportunities for long-term investors who trust in Humana’s ability to navigate its current challenges successfully.
Frequently Asked Questions
What is the current star rating for Humana's plans?
Humana's recent disclosure revealed that only 25% of its members will be enrolled in plans rated 4 stars or above for 2025.
How has TD Cowen rated Humana recently?
TD Cowen has maintained a Buy rating on Humana, sustaining a price target of $402.00 despite the recent rating challenges.
What financial impacts are expected due to the rating drop?
The decrease in star ratings could significantly affect Humana's premiums in 2026 and impact the company's earnings per share and profit margins.
Which companies have retained ratings on Humana?
Barclays has maintained an Overweight rating, while Morgan Stanley and JPMorgan have kept their Neutral ratings. However, Leerink Partners downgraded Humana from Outperform to Market Perform.
How has Humana performed financially in recent times?
Humana reported a revenue of $112.04 billion for the last twelve months as of Q2 2024, indicating a revenue growth of 13.48% during that period.
